Calypso Biotech begins dosing of first Eosinophilic Esophagitis patient in trial of CALY-002
Calypso Biotech, a leader in the development of Interleukin-15 (IL-15) targeted therapies, has begun dosing of the first Eosinophilic Esophagitis patient in the multiple dosing part of the Phase 1 clinical trial of CALY-002, a novel humanized – and highly differentiated – monoclonal antibody neutralizing IL-15. The ongoing Phase 1 clinical study of CALY-002 includes […]